Research ExplorerPublicationsValidation of the STAR-CAP Clinical Prognostic System for Pr...

Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort

Standard

Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort. / Würnschimmel, Christoph; Pose, Randi Marisa; Wenzel, Mike; Tian, Zhe; Incesu, Reha-Baris; Karakiewicz, Pierre; Graefen, Markus; Tilki, Derya.

In: EUR UROL, Vol. 80, No. 4, 10.2021, p. 400-404.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Würnschimmel, C, Pose, RM, Wenzel, M, Tian, Z, Incesu, R-B, Karakiewicz, P, Graefen, M & Tilki, D 2021, 'Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort', EUR UROL, vol. 80, no. 4, pp. 400-404. https://doi.org/10.1016/j.eururo.2021.06.008

APA

Würnschimmel, C., Pose, R. M., Wenzel, M., Tian, Z., Incesu, R-B., Karakiewicz, P., Graefen, M., & Tilki, D. (2021). Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort. EUR UROL, 80(4), 400-404. https://doi.org/10.1016/j.eururo.2021.06.008

Vancouver

Würnschimmel C, Pose RM, Wenzel M, Tian Z, Incesu R-B, Karakiewicz P et al. Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort. EUR UROL. 2021 Oct;80(4):400-404. https://doi.org/10.1016/j.eururo.2021.06.008

Bibtex

@article{7674f880dc2d4dd59b96f4742c5d824d,
title = "Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort",
abstract = "The proposed international staging collaboration for cancer of the prostate (STAR-CAP) clinical prognostic system for prostate cancer predicts cancer-specific mortality (CSM) for patients for whom active treatment, such as radical prostatectomy (RP), is planned. Until now, no validation of STAR-CAP has been performed. We retrospectively analyzed data from our institutional database for 19 552 patients treated with RP between 1992 and 2015. We applied the STAR-CAP point assignment criteria to calculate total individual scores and then classified patients according to the STAR-CAP stage groups ranging from IA (lowest risk) to IIIC (highest risk). We evaluated biochemical recurrence (BCR)-free survival, metastasis-free survival (MFS), and cancer-specific survival (CSS) stratified by STAR-CAP stage groups over 10 yr, calculated the area under the receiver operating characteristics curve (AUC), and performed decision curve analyses to assess the ability of STAR-CAP to predict these outcomes after fitting the data from our single-institution data set. STAR-CAP performed well in stratifying individual survival outcomes for BCR-free survival, MFS, and CSS for each stage group in Kaplan-Meier analyses (p < 0.001 between groups). The AUC for prediction of BCR, metastasis, and CSM at 10 yr was 0.73, 0.84, and 0.75, respectively. Our findings validate the performance of STAR-CAP for European patients treated with RP. PATIENT SUMMARY: We validated the STAR-CAP system for predicting cancer outcomes after removal of the prostate. Our results show that the system performs well and could help in counseling patients with prostate cancer.",
author = "Christoph W{\"u}rnschimmel and Pose, {Randi Marisa} and Mike Wenzel and Zhe Tian and Reha-Baris Incesu and Pierre Karakiewicz and Markus Graefen and Derya Tilki",
note = "Copyright {\textcopyright} 2021. Published by Elsevier B.V.",
year = "2021",
month = oct,
doi = "10.1016/j.eururo.2021.06.008",
language = "English",
volume = "80",
pages = "400--404",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Validation of the STAR-CAP Clinical Prognostic System for Predicting Biochemical Recurrence, Metastasis, and Cancer-specific Mortality After Radical Prostatectomy in a European Cohort

AU - Würnschimmel, Christoph

AU - Pose, Randi Marisa

AU - Wenzel, Mike

AU - Tian, Zhe

AU - Incesu, Reha-Baris

AU - Karakiewicz, Pierre

AU - Graefen, Markus

AU - Tilki, Derya

N1 - Copyright © 2021. Published by Elsevier B.V.

PY - 2021/10

Y1 - 2021/10

N2 - The proposed international staging collaboration for cancer of the prostate (STAR-CAP) clinical prognostic system for prostate cancer predicts cancer-specific mortality (CSM) for patients for whom active treatment, such as radical prostatectomy (RP), is planned. Until now, no validation of STAR-CAP has been performed. We retrospectively analyzed data from our institutional database for 19 552 patients treated with RP between 1992 and 2015. We applied the STAR-CAP point assignment criteria to calculate total individual scores and then classified patients according to the STAR-CAP stage groups ranging from IA (lowest risk) to IIIC (highest risk). We evaluated biochemical recurrence (BCR)-free survival, metastasis-free survival (MFS), and cancer-specific survival (CSS) stratified by STAR-CAP stage groups over 10 yr, calculated the area under the receiver operating characteristics curve (AUC), and performed decision curve analyses to assess the ability of STAR-CAP to predict these outcomes after fitting the data from our single-institution data set. STAR-CAP performed well in stratifying individual survival outcomes for BCR-free survival, MFS, and CSS for each stage group in Kaplan-Meier analyses (p < 0.001 between groups). The AUC for prediction of BCR, metastasis, and CSM at 10 yr was 0.73, 0.84, and 0.75, respectively. Our findings validate the performance of STAR-CAP for European patients treated with RP. PATIENT SUMMARY: We validated the STAR-CAP system for predicting cancer outcomes after removal of the prostate. Our results show that the system performs well and could help in counseling patients with prostate cancer.

AB - The proposed international staging collaboration for cancer of the prostate (STAR-CAP) clinical prognostic system for prostate cancer predicts cancer-specific mortality (CSM) for patients for whom active treatment, such as radical prostatectomy (RP), is planned. Until now, no validation of STAR-CAP has been performed. We retrospectively analyzed data from our institutional database for 19 552 patients treated with RP between 1992 and 2015. We applied the STAR-CAP point assignment criteria to calculate total individual scores and then classified patients according to the STAR-CAP stage groups ranging from IA (lowest risk) to IIIC (highest risk). We evaluated biochemical recurrence (BCR)-free survival, metastasis-free survival (MFS), and cancer-specific survival (CSS) stratified by STAR-CAP stage groups over 10 yr, calculated the area under the receiver operating characteristics curve (AUC), and performed decision curve analyses to assess the ability of STAR-CAP to predict these outcomes after fitting the data from our single-institution data set. STAR-CAP performed well in stratifying individual survival outcomes for BCR-free survival, MFS, and CSS for each stage group in Kaplan-Meier analyses (p < 0.001 between groups). The AUC for prediction of BCR, metastasis, and CSM at 10 yr was 0.73, 0.84, and 0.75, respectively. Our findings validate the performance of STAR-CAP for European patients treated with RP. PATIENT SUMMARY: We validated the STAR-CAP system for predicting cancer outcomes after removal of the prostate. Our results show that the system performs well and could help in counseling patients with prostate cancer.

U2 - 10.1016/j.eururo.2021.06.008

DO - 10.1016/j.eururo.2021.06.008

M3 - Other (editorial matter etc.)

C2 - 34162491

VL - 80

SP - 400

EP - 404

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 4

ER -